PREFER-HF: Is iron therapy helpful in HFpEF with iron deficiency?

Iron therapy was not associated with functional or quality-of-life improvements in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency. However, there was a signal suggesting that iron could reduce hospitalisations, with oral and intravenous iron therapy displaying similar results. The phase 3 PREFER-HF trial (NCT03833336) randomised 72 patients with HF and a left ventricular ejection fraction >45% 1:1:1:1 to intravenous iron therapy, oral ferroglycine sulfate, oral sucrosomial iron, or a placebo [1]. The primary endpoint was improvement in the 6-minute walk test (6MWT) at 24 weeks. Iron therapy did not improve the distance achieved in the 6MWT compared with placebo in this population (-1.51 m vs +5.97 m; P=0.80). Iron therapy also did not improve quality-of-life in these participants. Although the primary endpoint was no...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 22 May 202517 July 2025